Centrus Energy - LEU Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centrus Energy in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LEU shares.
View LEU analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Centrus Energy's shares. Their LEU share price forecasts range from $48.00 to $70.00. On average, they anticipate the company's stock price to reach $59.00 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price.
View analysts price targets for LEU or view top-rated stocks among Wall Street analysts.

Centrus Energy's stock was trading at $43.45 at the beginning of 2022. Since then, LEU stock has decreased by 1.4% and is now trading at $42.85.
View the best growth stocks for 2022 here.

Centrus Energy saw a increase in short interest in August. As of August 31st, there was short interest totaling 518,600 shares, an increase of 7.2% from the August 15th total of 483,600 shares. Based on an average daily volume of 199,100 shares, the short-interest ratio is currently 2.6 days. Approximately 4.5% of the shares of the company are sold short.
View Centrus Energy's Short Interest.

Centrus Energy Corp. (NYSEAMERICAN:LEU) announced its quarterly earnings results on Thursday, August, 4th. The basic materials company reported $2.51 EPS for the quarter, topping analysts' consensus estimates of $0.80 by $1.71. The basic materials company had revenue of $99.10 million for the quarter, compared to analysts' expectations of $66.30 million. Centrus Energy had a net margin of 62.06% and a negative trailing twelve-month return on equity of 151.11%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Centrus Energy investors own include Ampio Pharmaceuticals (AMPE), Arbutus Biopharma (ABUS), Aeterna Zentaris (AEZS), Align Technology (ALGN), CTI BioPharma (CTIC), CEL-SCI (CVM), Genocea Biosciences (GNCA), Palatin Technologies (PTN), Vascular Biogenics (VBLT) and Agenus (AGEN).

Centrus Energy trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LEU."

Centrus Energy's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sara Bay Financial (2.59%), Renaissance Technologies LLC (2.29%), State Street Corp (1.47%), Dupont Capital Management Corp (0.72%), Northern Trust Corp (0.67%) and Point72 Asset Management L.P. (0.65%). Insiders that own company stock include Daniel B Poneman, Dennis John Scott, John C Dorrian, John M A Donelson, Larry B Cutlip, Morris Bawabeh, Neil S Subin and Philip O Strawbridge.
View institutional ownership trends.

Shares of LEU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LEU stock can currently be purchased for approximately $42.85.

Centrus Energy (NYSEAMERICAN:LEU) has a market capitalization of $620.85 million and generates $298.30 million in revenue each year. The basic materials company earns $175 million in net income (profit) each year or $11.40 on an earnings per share basis.

The company employs 266 workers across the globe.

Centrus Energy's mailing address is 6901 ROCKLEDGE DR SUITE 800, BETHESDA MD, 20817. The official website for the company is www.centrusenergy.com. The basic materials company can be reached via phone at (301) 564-3200, via email at financial@centrusenergy.com, or via fax at 301-564-3201.